Filing Details

Accession Number:
0001562180-23-002039
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-03-01 16:06:17
Reporting Period:
2023-02-27
Accepted Time:
2023-03-01 16:06:17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1517022 Akebia Therapeutics Inc. AKBA Pharmaceutical Preparations (2834) 208756903
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1669737 Michel Dahan C/O Akebia Therapeutics, Inc.
245 First Street
Cambridge MA 02142
Svp, Chief Operating Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-02-27 10,090 $0.81 289,927 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021.
  2. Includes 1,500 shares of the Issuers common stock purchased on June 30, 2022, and 1,500 shares of the Issuers common stock purchased on December 30, 2022, each under the Issuer's 2014 Amended and Restated Employee Stock Purchase Plan.